Commitments and Contingencies - License Agreements - Additional Information (Details) - TMRC - USD ($) |
1 Months Ended | 3 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2016 |
May 31, 2016 |
Sep. 30, 2015 |
Mar. 31, 2021 |
Mar. 31, 2020 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
| Up-front license fee | $ 1,000,000.0 | ||||
| Payment of up-front license fee | $ 500,000 | 500,000 | |||
| Payments per indication due upon the successful achievement of clinical and regulatory milestones | $ 13,000,000.0 | ||||
| Payments made upon achievement of development milestone | $ 1,000,000.0 | ||||
| Fees incurred under supply management agreement | $ 0 | $ 300,000 | |||
| X | ||||||||||
- Definition Payments made per the license agreement, for a development milestone achieved. No definition available.
|
| X | ||||||||||
- Definition The payments per indication due upon the successful achievement of clinical and regulatory milestones. No definition available.
|
| X | ||||||||||
- Definition Represents fees incurred under the supply management agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of the up-front license fee. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of the up-front license fee payments made during the period. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|